Physician profile
Robert P Neubauer
NPI 1902435571
$1,009.05
in general payments reported to CMS, 2019-2025
13 companies · $979 in 2025
The $979 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2022: $15.72 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.54 | 2022-2025 | Wegovy, Saxenda, Rybelsus |
| Exact Sciences Corporation | $134.30 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $113.57 | 2025 | |
| Lilly USA, LLC | $107.53 | 2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $96.52 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $93.75 | 2025 | Airsupra, Andexxa |
| Abbvie INC. | $63.63 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.74 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.78 | 2025 | Jardiance |
| Viiv Healthcare Company | $13.91 | 2019 | |
| Amgen INC. | $13.49 | 2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $9.83 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Neubauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.